Linda M Pilarski

List of Publications by Year
in descending order

136 papers	5,685 citations	66343 42 h-index	85541 71 g-index
137 all docs	137 docs citations	137 times ranked	4947 citing authors

#	Article	IF	Citations
1	Genetics and Cytogenetics of Multiple Myeloma. Cancer Research, 2004, 64, 1546-1558.	0.9	642
2	In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood, 2003, 101, 1520-1529.	1.4	356
3	RHAMM Is a Centrosomal Protein That Interacts with Dynein and Maintains Spindle Pole Stability. Molecular Biology of the Cell, 2003, 14, 2262-2276.	2.1	167
4	Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood, 2005, 105, 4060-4069.	1.4	159
5	A High Frequency of Circulating B Cells Share Clonotypic Ig Heavy-Chain VDJ Rearrangements With Autologous Bone Marrow Plasma Cells in Multiple Myeloma, as Measured by Single-Cell and In Situ Reverse Transcriptase-Polymerase Chain Reaction. Blood, 1998, 92, 2844-2855.	1.4	134
6	Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone. Blood, 1999, 93, 1287-1298.	1.4	133
7	Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood, 2000, 95, 1056-1065.	1.4	127
8	Monoclonal Circulating B Cells in Multiple Myeloma. Hematology/Oncology Clinics of North America, 1992, 6, 297-322.	2.2	126
9	CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications. Journal of Immunotherapy, 2002, 25, 72-81.	2.4	123
10	A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood, 2008, 112, 2935-2945.	1.4	110
11	Definition of the thymic generative lineage by selective expression of high molecular weight isoforms of CD45 (T200). European Journal of Immunology, 1989, 19, 589-597.	2.9	108
12	CD34+ Cells in the Blood of Patients With Multiple Myeloma Express CD19 and IgH mRNA and Have Patient-Specific IgH VDJ Gene Rearrangements. Blood, 1997, 89, 1824-1833.	1.4	107
13	An inexpensive and portable microchip-based platform for integrated RTâ€"PCR and capillary electrophoresis. Analyst, The, 2008, 133, 331.	3.5	99
14	Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood, 2004, 104, 2134-2142.	1.4	95
15	Overexpression of the Receptor for Hyaluronan-Mediated Motility (RHAMM) Characterizes the Malignant Clone in Multiple Myeloma: Identification of Three Distinct RHAMM Variants. Blood, 1999, 93, 1684-1696.	1.4	92
16	Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leukemia and Lymphoma, 2006, 47, 2289-2300.	1.3	90
17	MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells. Immunology and Cell Biology, 2017, 95, 611-619.	2.3	90
18	RHAMM, a Receptor for Hyaluronan-Mediated Motility, on Normal Human Lymphocytes, Thymocytes and Malignant B Cells: a Mediator in B cell Malignancy?. Leukemia and Lymphoma, 1994, 14, 363-374.	1.3	86

#	Article	IF	Citations
19	Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood, 2000, 96, 3147-3153.	1.4	86
20	RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood, 2004, 104, 1151-1158.	1.4	85
21	Potential Role for Hyaluronan and the Hyaluronan Receptor RHAMM in Mobilization and Trafficking of Hematopoietic Progenitor Cells. Blood, 1999, 93, 2918-2927.	1.4	83
22	Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Research, 2005, 65, 850-60.	0.9	73
23	Transition in CD45 isoform expression during differentiation of normal and abnormal B cells. International Immunology, 1989, 1, 229-236.	4.0	72
24	Multidrug transporter p-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: Modulation with differentiation stage and during aging. American Journal of Hematology, 1995, 49, 323-335.	4.1	71
25	ANALYSIS OF PERIPHERAL BLOOD LYMPHOCYTE POPULATIONS AND IMMUNE FUNCTION FROM CHILDREN EXPOSED TO CYCLOSPORINE OR TO AZATHIOPRINE IN UTERO. Transplantation, 1994, 57, 133-143.	1.0	70
26	Automated screening using microfluidic chip-based PCR and product detection to assess risk of BK virus-associated nephropathy in renal transplant recipients. Electrophoresis, 2006, 27, 3753-3763.	2.4	70
27	Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells. Journal of Liposome Research, 1999, 9, 199-228.	3.3	67
28	Expression of multiple Î²1 integrins on circulating monoclonal B cells in patients with multiple myeloma. American Journal of Hematology, 1993, 43, 29-36.	4.1	64
29	Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood, 2005, 105, 4836-4844.	1.4	61
30	Establishment of BCWM.1 cell line for WaldenstrÃ¶m's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Experimental Hematology, 2007, 35, 1366-1375.	0.4	61
31	Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Experimental Hematology, 2002, 30, 221-228.	0.4	59
32	Circulating Clonotypic B Cells in the Biology of Multiple Myeloma: Speculations on the Origin of Myeloma. Leukemia and Lymphoma, 1996, 22, 375-383.	1.3	58
33	The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. British Journal of Haematology, 2008, 140, 295-302.	2.5	58
34	Deficient Drug Transporter Function of Bone Marrowâ€"Localized and Leukemic Plasma Cells in Multiple Myeloma. Blood, 1997, 90, 3751-3759.	1.4	55
35	SSX Cancer Testis Antigens are Expressed in Most Multiple Myeloma Patients. Journal of Immunotherapy, 2005, 28, 564-575.	2.4	53
36	An integrated microfluidic chip for chromosome enumeration using fluorescence in situ hybridization. Lab on A Chip, 2008, 8, 2151.	6.0	53

#	Article	IF	Citations
37	Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function. Journal of Clinical Immunology, 1986, 6, 491-501.	3.8	52
38	Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood, 2001, 98, 2791-2799.	1.4	52
39	Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients. Journal of Clinical Immunology, 1988, 8, 259-265.	3.8	49
40	Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochimica Et Biophysica Acta - Biomembranes, 2000, 1466, 205-220.	2.6	47
41	Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clinical Cancer Research, 2002, 8, 3198-204.	7.0	46
42	Selective expression of CD45 isoforms and of maturation antigens during human thymocyte differentiation: observations and hypothesis. Immunology Letters, 1989, 21, 187-198.	2.5	42
43	Antigen-specific suppression of cytotoxic T cell responses in mice. I. Suppressor T cells are not cytotoxic cells. European Journal of Immunology, 1978, 8, 504-511.	2.9	41
44	HMMR acts in the PLK1-dependent spindle positioning pathway and supports neural development. ELife, 2017, 6, .	6.0	41
45	Impaired class switch recombination (CSR) in Waldenstroĭ̂m macroglobulinemia (WM) despite apparently normal CSR machinery. Blood, 2006, 107, 2920-2927.	1.4	39
46	The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma. PLoS ONE, 2013, 8, e58504.	2.5	38
47	Abnormalities in lymphocyte profile and specificity repertoire of patients with Waldenstrom's macroglobulinemia, multiple myeloma, and IgM monoclonal gammopathy of undetermined significance. American Journal of Hematology, 1989, 30, 53-60.	4.1	37
48	Intrinsic Expression of the Multidrug Transporter, P-Glycoprotein 170, in Multiple Myeloma: Implications for Treatment. Leukemia and Lymphoma, 1995, 17, 367-374.	1.3	37
49	Spatial regulation of Aurora A activity during mitotic spindle assembly requires RHAMM to correctly localize TPX2. Cell Cycle, 2014, 13, 2248-2261.	2.6	37
50	Transitions in CD45 isoform expression indicate continuous differentiation of a monoclonal CD5+ CD11b+ B lineage in Waldenstrom's macroglobulinemia. American Journal of Hematology, 1991, 37, 20-30.	4.1	36
51	Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma. Experimental Hematology, 2001, 29, 1076-1081.	0.4	36
52	Altered Expression of Fibronectin and Collagens I and IV in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. Journal of Histochemistry and Cytochemistry, 2009, 57, 239-247.	2.5	35
53	Generation of antibody diversity. I. Kinetics of production of different antibody specificities during the course of an immune response. European Journal of Immunology, 1974, 4, 319-326.	2.9	34
54	Molecular Characterization of Waldenstrom's Macroglobulinemia Reveals Frequent Occurrence of Two B-Cell Clones Having Distinct IgH VDJ Sequences. Clinical Cancer Research, 2007, 13, 2005-2013.	7.0	34

#	Article	IF	Citations
55	Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. Blood, 2008, 112, 5111-5121.	1.4	30
56	On-chip PCR amplification of genomic and viral templates in unprocessed whole blood. Microfluidics and Nanofluidics, 2011, 10, 697-702.	2.2	30
57	The generation of antibody diversity. III. Variation in the specificity of antibody produced within single clones of antibody-forming cellsin vitro. European Journal of Immunology, 1974, 4, 762-767.	2.9	29
58	In-Gel Technology for PCR Genotyping and Pathogen Detection. Analytical Chemistry, 2010, 82, 8079-8087.	6.5	29
59	Origins of WaldenstrÃ¶m's Macroglobulinemia: Does It Arise from an Unusual B-Cell Precursor?. Clinical Lymphoma and Myeloma, 2005, 5, 217-219.	2.1	28
60	Aberrant Splice Variants of HAS1 (Hyaluronan Synthase 1) Multimerize with and Modulate Normally Spliced HAS1 Protein. Journal of Biological Chemistry, 2009, 284, 18840-18850.	3.4	28
61	Microfluidic Platform for Single Nucleotide Polymorphism Genotyping of the Thiopurine S-Methyltransferase Gene to Evaluate Risk for Adverse Drug Events. Journal of Molecular Diagnostics, 2007, 9, 521-529.	2.8	27
62	Addressing heterogeneity of individual blood cancers: the need for single cell analysis. Cell Biology and Toxicology, 2017, 33, 83-97.	5.3	27
63	Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulimenia. Seminars in Oncology, 2003, 30, 165-168.	2.2	25
64	Single-Cell Analysis and Next-Generation Immuno-Sequencing Show That Multiple Clones Persist in Patients with Chronic Lymphocytic Leukemia. PLoS ONE, 2015, 10, e0137232.	2.5	24
65	The malignant clone in Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 132-135.	2.2	22
66	Microfluidic Chips for Detecting the t(4;14) Translocation and Monitoring Disease during Treatment Using Reverse Transcriptase-Polymerase Chain Reaction Analysis of IgH-MMSET Hybrid Transcripts. Journal of Molecular Diagnostics, 2007, 9, 358-367.	2.8	22
67	Antigen-specific helper T cells are essential for cytotoxic T cell responses to metabolically inactivated stimulator cells. European Journal of Immunology, 1979, 9, 454-460.	2.9	21
68	Specificity repertoire of lymphocytes from multiple myeloma patients. I. High frequency of B cells specific for idiotypic and F(ab?)2-region determinants on immunoglobulin. Journal of Clinical Immunology, 1985, 5, 275-284.	3.8	21
69	Cell generation within human thymic subsets defined by selective expression of CD45 (T200) isoforms. Human Immunology, 1990, 27, 333-347.	2.4	20
70	Inhibition of on-chip PCR using PDMSâ€“glass hybrid microfluidic chips. Microfluidics and Nanofluidics, 2012, 13, 383-398.	2.2	20
71	Balancing Thymocyte Adhesion and Motility: A Functional Linkage Between Î²1 Lntegrins and The Motility Receptor RHAMM. Autoimmunity, 2000, 7, 209-225.	0.6	19
72	Intraclonal homogeneity of clonotypic immunoglobulin M and diversity of nonclinical post-switch isotypes in multiple myeloma: insights into the evolution of the myeloma clone. Clinical Cancer Research, 2002, 8, 502-13.	7.0	18

#	Article	IF	Citations
73	The generation of antibody diversity. II. Plaque morphology as a simple marker for antibody specificity at the single-cell level. European Journal of Immunology, 1974, 4, 757-761.	2.9	17
74	Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist during Treatment with Rituximab. Clinical Medicine Oncology, 2008, 2, CMO.S615.	0.3	17
75	Generation of antibody dieversity. IV. Variation within single clones of antibody-forming cells developingin vivo. European Journal of Immunology, 1975, 5, 10-16.	2.9	16
76	Surface markers on the T cells that regulate cytotoxic T-cell responses. Immunogenetics, 1980, 10, 521-533.	2.4	16
77	Analysis of immunodeficiency in multiple myeloma: Observations and hypothesis. Journal of Clinical Laboratory Analysis, 1987, 1, 214-228.	2.1	16
78	Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node, and bone marrow from a terminal myeloma patient. American Journal of Hematology, 1992, 41, 199-208.	4.1	16
79	Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny. Blood, 2008, 112, 1894-1903.	1.4	16
80	During human thymic development, Î²1 integrins regulate adhesion, motility, and the outcome of RHAMM/hyaluronan engagement. Journal of Leukocyte Biology, 1998, 64, 781-790.	3.3	15
81	Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma. Leukemia Research, 2011, 35, 1637-1643.	0.8	14
82	Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood, 2000, 96, 3147-3153.	1.4	14
83	BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells. Oncotarget, 2017, 8, 32461-32475.	1.8	14
84	CD45 isoform transitions on multinegative human thymocytes differentiatingin vitromimic patterns predicted for selective eventsin vivo. Immunology and Cell Biology, 1993, 71, 289-301.	2.3	13
85	Frequent Occurrence of Highly Expanded but Unrelated B-Cell Clones in Patients with Multiple Myeloma. PLoS ONE, 2013, 8, e64927.	2.5	13
86	Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma. Journal of Immunological Methods, 2005, 305, 94-105.	1.4	12
87	Aurora Kinases as Therapeutic Targets in Multiple Myeloma.. Blood, 2006, 108, 847-847.	1.4	12
88	Localization of endogenous galactoside-binding lectin during morphogenesis ofXenopus laevis. Anatomy and Embryology, 1990, 182, 319-327.	1.5	11
89	A Three-dimensional Tissue Culture Model to Study Primary Human Bone Marrow and its Malignancies. Journal of Visualized Experiments, 2014, , .	0.3	11
90	Aberrant Posttranscriptional Processing of Hyaluronan Synthase 1 in Malignant Transformation and Tumor Progression. Advances in Cancer Research, 2014, 123, 67-94.	5.0	11

#	Article	IF	Citations
91	Theoretical Article Adhesive interactions in thymic development: Does selective expression of CD45 isoforms promote stageâ€specific microclustering in the assembly of functional adhesive complexes on differentiating T lineage lymphocytes?. Immunology and Cell Biology, 1993, 71, 59-69.	2.3	10
92	Drug Resistance in Multiple Myeloma: Novel Therapeutic Targets Within the Malignant Clone. Leukemia and Lymphoma, 1999, 32, 199-210.	1.3	10
93	Potential Impact of a Single Nucleotide Polymorphism in the Hyaluronan Synthase 1 Gene in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 253-256.	2.1	10
94	Strategies for enhancing the speed and integration of microchip genetic amplification. Electrophoresis, 2008, 29, 4684-4694.	2.4	10
95	Suppressor T cells derived from early postnatal murine spleen inhibit cytotoxic T-cell responses. Cellular Immunology, 1981, 58, 345-355.	3.0	9
96	Genotyping Single Nucleotide Polymorphisms in Human Genomic DNA with an Automated and Self-Contained PCR Cassette. Journal of Molecular Diagnostics, 2014, 16, 550-557.	2.8	9
97	Detection of pathogenic Escherichia coli on potentially contaminated beef carcasses using cassette PCR and conventional PCR. BMC Microbiology, 2019, 19, 175.	3.3	9
98	Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone. Blood, 1999, 93, 1287-1298.	1.4	9
99	In multiple myeloma, boneâ€marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival. American Journal of Hematology, 2012, 87, 579-587.	4.1	8
100	Differential nuclear organization of translocationâ€prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma. Genes Chromosomes and Cancer, 2013, 52, 523-537.	2.8	8
101	Alteration of Introns in a Hyaluronan Synthase 1 (HAS1) Minigene Convert Pre-Mrna Splicing to the Aberrant Pattern in Multiple Myeloma (MM): MM Patients Harbor Similar Changes. PLoS ONE, 2013, 8, e53469.	2.5	8
102	CD34+ Cells in the Blood of Patients With Multiple Myeloma Express CD19 and IgH mRNA and Have Patient-Specific IgH VDJ Gene Rearrangements. Blood, 1997, 89, 1824-1833.	1.4	8
103	A new system for highly efficient generation of alloantigen-specific cytotoxic T cells. European Journal of Immunology, 1976, 6, 906-909.	2.9	7
104	An analysis of B Cell memory. Cellular Immunology, 1978, 40, 376-388.	3.0	7
105	Identification of Clonotypic IgH VDJ Sequences in Multiple Myeloma. , 2005, 113, 121-144.		7
106	Sub-microliter scale in-gel loop-mediated isothermal amplification (LAMP) for detection of Mycobacterium tuberculosis. Microfluidics and Nanofluidics, 2013, 14, 731-741.	2.2	7
107	A High Frequency of Circulating B Cells Share Clonotypic Ig Heavy-Chain VDJ Rearrangements With Autologous Bone Marrow Plasma Cells in Multiple Myeloma, as Measured by Single-Cell and In Situ Reverse Transcriptase-Polymerase Chain Reaction. Blood, 1998, 92, 2844-2855.	1.4	7
108	Potential Role for Hyaluronan and the Hyaluronan Receptor RHAMM in Mobilization and Trafficking of Hematopoietic Progenitor Cells. Blood, 1999, 93, 2918-2927.	1.4	7

#	Article	IF	Citations
109	Inherited Polymorphisms in Hyaluronan Synthase 1 Predict Risk of Systemic B-Cell Malignancies but Not of Breast Cancer. PLoS ONE, 2014, 9, e100691.	2.5	7
110	A potential role for centrosomal deregulation within IgH translocation-positive myeloma. Medical Hypotheses, 2005, 65, 915-921.	1.5	4
111	Promiscuity of translocation partners in multiple myeloma. Journal of Cellular Biochemistry, 2010, 109, 1085-1094.	2.6	4
112	Multiple myeloma may include microvessel endothelial cells of malignant origin. Leukemia and Lymphoma, 2010, 51, 592-597.	1.3	4
113	Differential positioning and close spatial proximity of translocationâ€prone genes in nonmalignant Bâ€cells from multiple myeloma patients. Genes Chromosomes and Cancer, 2012, 51, 727-742.	2.8	4
114	Monitoring food pathogens: Novel instrumentation for cassette PCR testing. PLoS ONE, 2018, 13, e0197100.	2.5	4
115	Circulating B Lymphocytes from Patients with Multiple Myeloma Harbour T(4;14) Translocations and Chromosome 13 Deletions.. Blood, 2005, 106, 500-500.	1.4	4
116	Clonal expansion of IgM B memory cells in vitro. Cellular Immunology, 1978, 40, 389-394.	3.0	3
117	Deficiency of mature B and T lymphocyte subsets in the blood of non-Hodgkin lymphoma patients. American Journal of Hematology, 1987, 26, 125-134.	4.1	3
118	Genetic Abnormalities in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 30-32.	1.4	3
119	In a patient with biclonal Waldenstrom macroglobulinemia only one clone expands in three-dimensional culture and includes putative cancer stem cells. Leukemia and Lymphoma, 2011, 52, 285-289.	1.3	3
120	<i>FGFR3</i> preferentially colocalizes with <i>IGH</i> in the interphase nucleus of multiple myeloma patient Bâ€cells when <i>FGFR3</i> is located outside of CT4. Genes Chromosomes and Cancer, 2016, 55, 962-974.	2.8	3
121	Application of lab-on-a-chip multiplex cassette PCR for the detection of enterohemorrhagic Escherichia coli. BMC Microbiology, 2019, 19, 93.	3.3	3
122	The Malignant Hierarchy in Multiple Myeloma: Relationships between Malignant Cells and Bone Disease. Cancer Metastasis - Biology and Treatment, 2004, , 109-138.	0.1	3
123	Overexpression of the Receptor for Hyaluronan-Mediated Motility (RHAMM) Characterizes the Malignant Clone in Multiple Myeloma: Identification of Three Distinct RHAMM Variants. Blood, 1999, 93, 1684-1696.	1.4	3
124	Differential modulation of human multinegative (CD3^{âˆ’} 4 ^{âˆ’} 8 ^{âˆ’}) thymocyte proliferation by monoclonal antibodies to CD45RA or to CD45. Immunology and Cell Biology, 1994, 72, 292-299.	2.3	2
125	In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival. Molecular Cancer, 2012, 11, 78.	19.2	2
126	Discussion on the safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology, 2003, 125, 1562.	1.3	1

#	Article	IF	Citations
127	VDJ-Switch Region Analysis in Multiple Myeloma Patients Reveals Homogeneity and Long-Term Stability of Switch Junctions, and Ongoing Mutation Upstream of Switch Mu.. Blood, 2004, 104, 1414-1414.	1.4	1
128	Microfluidic Devices for Molecular Monitoring of Clonotypic IgH VDJ Signatures and the T(4;14) Translocation in Multiple Myeloma.. Blood, 2005, 106, 1536-1536.	1.4	1
129	Soluble Antigen-Specific Helper Molecules Active in the Induction of Cytotoxic T Lymphocytes. Annals of the New York Academy of Sciences, 1988, 532, 136-148.	3.8	0
130	Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis. , 2017, , 35-48.		0
131	Comparison of a Miniaturized Cassette PCR System with a Commercially Available Platform for Detecting Escherichia coli in Beef Carcass Swabs. Micromachines, 2021, 12, 959.	2.9	0
132	Mutator Genes UDG and AID Appear To Be Normal in Class-Switch Deficient and Clonally Homogeneous Waldenstromâ€™s Macroglobulinemias Having Either Germline or Hypermutated Clonotypic IgH VDJ.. Blood, 2004, 104, 1359-1359.	1.4	0
133	Genomic Instability in Multiple Myeloma: Inducible Transfectants Provide a Model To Define the Role of RHAMM and Centrosome/Mitotic Spindle Stability in Myelomagenesis.. Blood, 2006, 108, 5037-5037.	1.4	0
134	Germline and Somatic Mutations in the Hyaluronan Synthaseâ€“1 (HAS1) Gene May Contribute to Oncogenesis in Multiple Myeloma (MM) and Waldenstromâ€™s Macroglobulinemia (WM).. Blood, 2007, 110, 2488-2488.	1.4	0
135	Pre-Clinical Validation of Polo-Like Kinase 1 as a Therapeutic Target in Multiple Myeloma with the Selective Inhibitor BI2536.. Blood, 2007, 110, 2514-2514.	1.4	0
136	Splicing Mutations in the Hyaluronan Synthase I Gene of Patients with Monoclonal Gammopathy of Undetermined Significance.. Blood, 2009, 114, 2841-2841.	1.4	0